09.00 (1) David Back - BHIVA · WeBhaveBrecentlyBexpandedBourBinteractionBclassificationBtoB...
21
Update on Liverpool Drug Interaction Team Activities David Back
Transcript of 09.00 (1) David Back - BHIVA · WeBhaveBrecentlyBexpandedBourBinteractionBclassificationBtoB...
Update on Liverpool Drug Interaction Team Activities
David Back
1. Analytics
2. Expansion of the Interaction Classification
3. Other ongoing projects.
4. New Drugs
5. New Site
HIV annual site visits 2010-16
107,677
135,987 145,686
159,470
181,009
235,990
282,037
-‐
50,000
100,000
150,000
200,000
250,000
300,000
2010 2011 2012 2013 2014 2015 2016
Google Analytics
HIV average monthly visitors 2010-16
5,497
6,977
7,943 8,771
9,922
12,831
13,891
-‐
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
2010 2011 2012 2013 2014 2015 2016
Google Analytics
HIV total app downloads 2010-16
1,459
13,568
24,424
34,860
45,639
58,133
70,795
-‐
10,000
20,000
30,000
40,000
50,000
60,000
70,000
80,000
2010 2011 2012 2013 2014 2015 2016
Google Analytics
HEP Annual site visits 2010-16
16,444
52,199 54,414 51,910
244,180
394,595
-‐
50,000
100,000
150,000
200,000
250,000
300,000
350,000
400,000
450,000
2011 2012 2013 2014 2015 2016
Google Analytics
HEP average monthly visitors 2010-16
949
2,824 3,072 2,961
10,336
17,238
-‐
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
18,000
20,000
2011 2012 2013 2014 2015 2016
Google Analytics
HEP total app downloads 2010-16
877
6,511
10,310
13,168
23,743
38,486
-‐
5,000
10,000
15,000
20,000
25,000
30,000
35,000
40,000
45,000
2011 2012 2013 2014 2015 2016
Google Analytics
Mixpanel
MixPanel: Real Time View
www.hiv-‐druginteractions.org
MixPanel: Top Co-Med Searches
www.hiv-‐druginteractions.org
MixPanel: Top Co-Med Searches
www.hiv-‐druginteractions.org
MixPanel – Top Co-med Searches: UKAmlodipineAtorvastatinRamiprilSimvastatinSidenafil
OmeprazoleLansoprazole
DoxycyclineRifampicinAmoxicillinClarithromycin
MirtazipineSertralineCitalopram
www.hiv-‐druginteractions.org
We have recently expanded our interaction classification to include a new ‘yellow’ classification. In contrast to the existing ‘amber’ interactions, which are ‘potentially clinically significant and likely to require additional monitoring, alteration of drug dosage or timing of administration’, the new yellow classification is for ‘potential interactions likely to be of weak intensity where additional action/monitoring or drug dosage adjustment is unlikely to be required’.
www.hep-‐druginteractions.orgAbbvie sa/nv – BEHCV170105 -‐ March 2017
Examples with 3D* Regimen
*Ombitasvir/Paritaprevir/ritonavir + Dasabuvir
Other Ongoing Projects
www.hiv-‐druginteractions.org
1. Translation
2. Linking of DDI database to other platforms/systems, ie electronic prescribing, patient-focussed apps etc
3. Charts and Educational Resources
Tokyo
Educational Resources
q 3 modules (each of 10, 15 min lectures) on
- Basic Drug Disposition and Pharmacokinetics- Pharmacology of Antiretrovirals- Pharmacology in Special Populations
Saye Khoo, David Back, Andrew Owen, Marco Siccardi, Marta Boffito, Catia Marzolini,David Burger
New Drugs 2017-
q Bictegravir (Ph 3)q Cabotegravir (Ph 3)q Doravarine (Ph 3)
q Glecaprevir/pibrentasvir (Ph 3)q Voxilaprevir (Ph 3)q Grazoprevir/ruzasvir/uprifosbuvir (Ph2)
Google Images
